The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study

Objective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and bone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study, 37 migraine patients took 600mg bid of Shi...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2019-01, Vol.2019 (2019), p.1-7
Main Authors: Han, Sung Ju, Chung, Jinyoung, Lee, Mijung, Won, Bohee, Jung, Yesol, Kim, Manho
Format: Article
Language:English
Subjects:
Arthritis
Bone diseases
Calcitonin
Calcitonin gene-related peptide
Comparative analysis
Cytokines
Drug dosages
Drug therapy
FDA approval
Headache
Headaches
Health aspects
Inflammatory diseases
Medical research
Medicine, Botanic
Medicine, Experimental
Medicine, Herbal
Medicine, Preventive
Migraine
Neurology
Nonsteroidal anti-inflammatory drugs
Pain
Patients
Peptides
Prescription drugs
Preventive health services
Questionnaires
Statistical analysis
Tumor necrosis factor-TNF
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and bone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study, 37 migraine patients took 600mg bid of Shinbaro for 12 weeks. At 4-week intervals, the migraine frequency and the rescue medications frequency were measured from each patient’s headache diary. The modified Migraine Disability Assessment (MIDAS) questionnaires to assess migraine associated disabilities were also completed at each visit. The serum calcitonin gene-related peptide (CGRP) concentrations before and after 12 weeks of Shinbaro administration were compared. Results. The monthly migraine frequency was significantly reduced from 20.5 days at baseline to 16.4 days at week 12 (P =0.003), and 22% of the participants showed ≥ 50% reduction. The frequency reduction was observed by week 4 (P =0.035) and continuously occurred through week 8 (P =0.001) and week 12 (P =0.003). The rescue medications frequency also decreased significantly from 17.4 days at baseline to 13.2 days at week 12 (P =0.035). Lastly, the serum CGRP concentration dropped from 434.6 pg/mL at baseline to 371.4 pg/mL at week 12, which was statistically significant (P
ISSN:1741-427X
1741-4288
DOI:10.1155/2019/2363420